RESUMO
Effectiveness of enalapril was studied in hypertensive patients with or without diabetes-mellitus. All the patients received enalapril, 5-20 mg per day for 9 months. Enalapril effectively controlled the blood pressure and favourably altered the lipid levels and did not affect the glucose level in diabetics as well as non-diabetics. Enalapril may be considered as a better therapeutic option for the treatment of hypertension associated with diabetes mellitus.
Assuntos
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Anti-Hipertensivos/sangue , Complicações do Diabetes , Diabetes Mellitus/sangue , Enalapril/uso terapêutico , Hipertensão/sangue , Hipertensão/tratamento farmacológico , Lipídeos/sangue , Idoso , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Anti-Hipertensivos/efeitos adversos , Glicemia/metabolismo , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Enalapril/efeitos adversos , Feminino , Humanos , Hipertensão/complicações , Masculino , Pessoa de Meia-IdadeRESUMO
A controlled clinical trial on 65 patients was performed to compare the effects of nifedipine and atenolol in diabetic and non-diabetic hypertensive patients. Patients were from 45 to 70 years in age. The diabetic hypertensive patients and non-diabetic essential hypertensive patients randomly received atenolol (50-100 mg per day) or nifedipine (10-20 mg per day) for 9 months. Both the drugs effectively controlled the blood pressure throughout the therapy. Atenolol treatment significantly increased triglyceride levels and decreased the HDL-cholesterol levels after 9 months in both groups. However, nifedipine therapy did not alter lipid levels to any significant extent. Both drugs did not alter blood glucose, serum creatinine and blood urea levels. It may be concluded from the present study that nifedipine is preferable to atenolol as it does not alter lipid profile to any significant extent in diabetic and non-diabetic hypertensive patients.